<DOC>
	<DOC>NCT02474550</DOC>
	<brief_summary>This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.</brief_summary>
	<brief_title>Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>- Newly diagnosed DLBCL patients treated with R-CHOP chemotherapy - Prphylactic peg-filgrastim on the day after chemotherapy</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>19 or older newly diagnosed with DLBCL RCHOP chemotherapy offer informed consent other subtype of NHL concomitant other cancer previous chemotherapy or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diffuse large b cell lymphoma</keyword>
	<keyword>peg-filgrastim</keyword>
	<keyword>febrile neutropenia</keyword>
</DOC>